# Does BPC-157 reduce inflammaging in older adults?

Canonical source: https://retacompare.com/research/does-bpc-157-reduce-inflammaging-in-older-adults

Peptide Longevity Q&A · 1999-12-01


    BPC-157 has demonstrated long-lasting cytoprotective effects in preclinical models of reflux oesophagitis, significantly reducing inflammatory cell presence compared to controls. This suggests potential benefits in managing chronic inflammation, a key factor in aging and age-related diseases.

 What the research shows

The study investigated the effects of pentadecapeptide BPC-157 and other anti-ulcer agents on reflux oesophagitis in gastrectomized rats. The research aimed to determine the long-term cytoprotective effects of these agents over periods of 1, 2, and 4 weeks. Euthanized rats were assessed for oesophagitis through both macroscopic and microscopic evaluations, focusing on ulceration areas, mucosal damage, and inflammatory cell counts. BPC-157 was administered continuously in drinking water, and its effects were compared with those of ranitidine, sucralfate, and cholestyramine.

 Why it matters for longevity

Chronic low-grade inflammation, often referred to as inflammaging, is associated with various age-related diseases and conditions. The findings from this study indicate that BPC-157 may help mitigate the inflammatory response in the gastrointestinal tract, which could have broader implications for managing chronic inflammation in aging populations. By demonstrating a reduction in inflammatory cell presence, BPC-157 may represent a potential therapeutic strategy for enhancing healthspan and longevity.

 Key findings at a glance

BPC-157 significantly reduced inflammatory cell counts in gastrectomized rats.

The peptide showed long-lasting cytoprotective effects over 28 days.

Other agents like ranitidine and sucralfate did not consistently demonstrate similar effects.

Macroscopic and microscopic assessments indicated less mucosal damage in BPC-157 treated groups.

The study supports the hypothesis of a common cytoprotective approach in treating reflux oesophagitis.

 How BPC-157 works (background)

BPC-157, a pentadecapeptide, is known for its cytoprotective properties. It has been shown to promote healing and reduce inflammation in various preclinical models. The mechanism of action is believed to involve the modulation of growth factors and cytokines that play a role in tissue repair and inflammatory responses. By enhancing mucosal defense and reducing inflammatory cell infiltration, BPC-157 may contribute to improved gastrointestinal health, potentially impacting overall healthspan.

 Safety, caveats, and what we don't yet know

This research is based on preclinical models, and while the results are promising, they cannot be directly extrapolated to human populations. Further studies are needed to evaluate the safety and efficacy of BPC-157 in humans, especially regarding long-term use and potential side effects. Additionally, the study focused on a specific condition (reflux oesophagitis), and the effects of BPC-157 on other inflammatory conditions remain to be explored.

 Bottom line

BPC-157 has shown potential in reducing chronic inflammation in a preclinical model, suggesting it may be beneficial for managing inflammaging. However, further research is necessary to confirm these effects in humans.

 Related questions

 Can BPC-157 enhance recovery from injuries?

Research indicates that BPC-157 may promote healing in various injury models, suggesting potential applications in recovery therapies.

 What role does BPC-157 play in gastrointestinal health?

BPC-157 has been shown to protect the gastrointestinal lining and reduce inflammation, indicating its importance in maintaining gastrointestinal health.

 Does BPC-157 have neuroprotective effects?

While primarily studied for its gastrointestinal benefits, some research suggests BPC-157 may also have neuroprotective properties, warranting further investigation.

 Source: PubMed · J Physiol Paris · published 1999-12-01.

## Sources

- PubMed · J Physiol Paris: https://pubmed.ncbi.nlm.nih.gov/10672991/